DS5 vs Vesilute
Side-by-side comparison of key properties, dosing, and research.
- Summary
- DS5 is a synthetic variant of the delta sleep-inducing peptide (DSIP), a nonapeptide originally isolated from rabbit cerebrospinal fluid during slow-wave sleep. Like DSIP, DS5 is explored for sleep optimization, stress modulation, and circadian rhythm normalization, with proposed improvements in potency or stability over the parent molecule.
- Vesilute is a tetrapeptide bioregulator (Lys-Glu-Asp-Leu) developed by Professor Vladimir Khavinson, tissue-specific for the retina and visual system. It supports retinal cell function, promotes normalization of photoreceptor protein synthesis, and is studied for age-related macular degeneration (AMD), retinal aging, and vision preservation in the elderly.
- Half-Life
- Estimated 30-60 minutes (peptide degradation)
- Short (minutes); sustained gene-regulatory effects
- Admin Route
- Subcutaneous, Intranasal (research)
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 200-500 mcg per dose
- 10 mg per day
- Frequency
- Once nightly
- Daily for 10–30 days
- Key Benefits
- Promotes delta-wave (deep) sleep and improves sleep quality
- May reduce sleep onset latency
- HPA axis modulation for stress reduction
- Non-addictive sleep support without tolerance development
- Potential circadian rhythm normalization
- Explored for insomnia, chronic stress, and PTSD-related sleep disturbance
- Supports retinal photoreceptor cell function and survival
- May slow progression of age-related macular degeneration
- Reduces retinal cell apoptosis from oxidative stress and aging
- Anti-aging effects on retinal pigment epithelium
- Potential support in diabetic retinopathy management
- Preserves visual acuity with aging
- Complementary to lutein, zeaxanthin, and NAD+ in ocular health protocols
- Side Effects
- Generally well-tolerated in research subjects
- Possible morning grogginess at higher doses
- Mild blood pressure fluctuations reported with DSIP
- Limited human safety data for DS5 specifically
- Generally well tolerated
- Mild injection site reactions
- No significant ocular adverse events reported at standard doses
- Stacks With
- —
- —